Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy

Epilepsy and Behavior

Volumn 18, Issue 3, 2010, Pages 229-237

  Gonzalez Heydrich, Joseph ^a   Whitney, Jane ^a   Waber, Deborah ^a   Forbes, Peter ^a   Hsin, Olivia ^a   Faraone, Stephen V ^b   Dodds, Alice ^a   Rao, Sneha ^a   Mrakotsky, Christine ^a   MacMillan, Carlene ^a   DeMaso, David R ^a   de Moor, Carl ^a   Torres, Alcy ^a   Bourgeois, Blaise ^a   Biederman, Joseph ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Attention deficit hyperactivity disorder; Childhood seizures; Epilepsy; Methylphenidate; OROS methylphenidate; Pharmacotherapy; Seizures; Stimulant

Indexed keywords

CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; METHYLPHENIDATE; OXCARBAZEPINE; PLACEBO; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEASIBILITY STUDY; FEMALE; HUMAN; INSOMNIA; MALE; MENTAL INSTABILITY; NAUSEA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE; BLOOD; COMPLICATION; CONFIDENCE INTERVAL; OUTCOME ASSESSMENT;

ADOLESCENT; ANTICONVULSANTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; HUMANS; MALE; METHYLPHENIDATE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 77954423766     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.02.022     Document Type: Article

References (36)

1. Hauser W.A., Annegers J.F., Rocca W.A. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996, 71:576-586.
2. Eriksson K.J., Koivikko M.J. Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. Epilepsia 1997, 38:1275-1282.
3. Sidenvall R., Forsgren L., Heijbel J. Prevalence and characteristics of epilepsy in children in northern Sweden. Seizure 1996, 5:139-146.
4. Bell G.S., Sander J.W. The epidemiology of epilepsy: the size of the problem. Seizure 2001, 10:306-314. quiz 315-6.
5. Waaler P.E., Blom B.H., Skeidsvoll H., Mykletun A. Prevalence, classification, and severity of epilepsy in children in western Norway. Epilepsia 2000, 41:802-810.
6. Dunn D.W., Austin J.K., Harezlak J., Ambrosius W.T. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003, 45:50-54.
7. Tan M., Appleton R. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy. Arch Dis Child 2005, 90:57-59.
8. Aldenkamp A.P., Arzimanoglou A., Reijs R., Van Mil S. Optimizing therapy of seizures in children and adolescents with ADHD. Neurology 2006, 67:S49-S51.
9. Thome-Souza S., Kuczynski E., Assumpcao F., et al. Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy?. Epilepsy Behav 2004, 5:988-994.
10. Adderall (p. 3165), Adderall XR (p. 3167), Concerta (p. 1883), 3176 Daytrana (p. 3176), Dexedrine (p. 1420), DextroStat (p. 3176), Focalin (p. 2221), Metadate (p. 3325), Ritalin (p. 2270), Ritalin LA (p. 2272), Ritalin SR (p. 2270). In: Physician's desk reference. 61st ed. Montvale, NJ: Thomson PDR; 2007.
11. Jadad A.R., Boyle M., Cunningham C., Kim M., Schachar R. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999, i-viii:1-341.
12. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999, 56:1073-1086.
13. MTA Cooperative Group Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry 1999, 56:1088-1096.
14. Baptista-Neto L., Dodds A., Rao S., Whitney J., Torres A., Gonzalez-Heydrich J. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs 2008, 17:77-84.
15. Plioplys S., Dunn D.W., Caplan R. 10-year research update review: psychiatric problems in children with epilepsy. J Am Acad Child Adolesc Psychiatry 2007, 46:1389-1402.
16. Torres A.R., Whitney J., Gonzalez-Heydrich J. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008, 12:217-233.
17. Feldman H., Crumrine P., Handen B.L., Alvin R., Teodori J. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 1989, 143:1081-1086.
18. Gross-Tsur V., Manor O., van der Meere J., Joseph A., Shalev R.S. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?. J Pediatr 1997, 130:670-674.
19. Gucuyener K., Erdemoglu A.K., Senol S., Serdaroglu A., Soysal S., Kockar A.I. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003, 18:109-112.
20. McGough J.J., McBurnett K., Bukstein O., et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006, 16:351-356.
21. Pelham W.E., Gnagy E.M., Burrows-Maclean L., et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001, 107:E105.
22. Wilens T.E., McBurnett K., Bukstein O., et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006, 160:82-90.
23. Eisenhauer E.A., O'Dwyer P.J., Christian M., Humphrey J.S. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000, 18:684-692.
24. Thall P.F., Lee J.J., Tseng C.H., Estey E.H. Accrual strategies for phase I trials with delayed patient outcome. Stat Med 1999, 18:1155-1169.
25. Ottman R., Hauser W.A., Stallone L. Semistructured interview for seizure classification: agreement with physicians' diagnoses. Epilepsia 1990, 31:110-115.
26. Ottman R., Lee J.H., Hauser W.A., et al. Reliability of seizure classification using a semistructured interview. Neurology 1993, 43:2526-2530.
27. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
28. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Assoc.; 1994.
29. Kaufman J., Birmaher B., Brent D., et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36:980-988.
30. Puig-Antich J., Orvaschel H., Tabrizi M., Chambers W. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version 1980, NY State Psychiatric Institute/Yale University School of Medicine, New York.
31. Wechsler D. Wechsler Abbreviated Scale of Intelligence 1999, Psychological Corp, San Antonio, TX.
32. Bruininks R.H., Woodcock R.W., Weatherman R.E., Hill B.K. Scales of Independent Behavior-Revised (SIB-R) 1996, Riverside, Chicago.
33. DuPaul G. The ADHD Rating Scale: normative data, reliability, and validity 1990, Univ. of Massachusetts Medical Center, Worcester.
34. DuPaul G.J., Power T.J., Anastopoulos A.D., Reid R. ADHD Rating Scale-IV: checklist, norms and clinical interpretations 1998, Guilford Press, New York.
35. Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology 1976, 218-221. Natl. Institute of Mental Health, Rockville, MD. W. Guy (Ed.).
36. Barkley R.A., McMurray M.B., Edelbrock C.S., Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic placebo-controlled evaluation. Pediatrics 1990, 86:184-192.